ANVS
Price
$3.60
Change
-$0.06 (-1.64%)
Updated
Dec 26 closing price
Capitalization
95.41M
86 days until earnings call
Intraday BUY SELL Signals
MDGL
Price
$598.91
Change
-$3.91 (-0.65%)
Updated
Dec 26 closing price
Capitalization
13.6B
67 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANVS vs MDGL

Header iconANVS vs MDGL Comparison
Open Charts ANVS vs MDGLBanner chart's image
Annovis Bio
Price$3.60
Change-$0.06 (-1.64%)
Volume$286.93K
Capitalization95.41M
Madrigal Pharmaceuticals
Price$598.91
Change-$3.91 (-0.65%)
Volume$97.81K
Capitalization13.6B
ANVS vs MDGL Comparison Chart in %
View a ticker or compare two or three
VS
ANVS vs. MDGL commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANVS is a Buy and MDGL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (ANVS: $3.60 vs. MDGL: $598.91)
Brand notoriety: ANVS and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANVS: 14% vs. MDGL: 27%
Market capitalization -- ANVS: $95.41M vs. MDGL: $13.6B
ANVS [@Biotechnology] is valued at $95.41M. MDGL’s [@Biotechnology] market capitalization is $13.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANVS’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • ANVS’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than ANVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANVS’s TA Score shows that 4 TA indicator(s) are bullish while MDGL’s TA Score has 4 bullish TA indicator(s).

  • ANVS’s TA Score: 4 bullish, 5 bearish.
  • MDGL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than ANVS.

Price Growth

ANVS (@Biotechnology) experienced а -1.37% price change this week, while MDGL (@Biotechnology) price change was +1.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

ANVS is expected to report earnings on Mar 23, 2026.

MDGL is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($13.6B) has a higher market cap than ANVS($95.4M). MDGL YTD gains are higher at: 94.092 vs. ANVS (-28.429). ANVS has higher annual earnings (EBITDA): -26.72M vs. MDGL (-270.14M). MDGL has more cash in the bank: 1.11B vs. ANVS (15.3M). MDGL has higher revenues than ANVS: MDGL (741M) vs ANVS (0).
ANVSMDGLANVS / MDGL
Capitalization95.4M13.6B1%
EBITDA-26.72M-270.14M10%
Gain YTD-28.42994.092-30%
P/E RatioN/AN/A-
Revenue0741M-
Total Cash15.3M1.11B1%
Total DebtN/A346M-
FUNDAMENTALS RATINGS
ANVS vs MDGL: Fundamental Ratings
ANVS
MDGL
OUTLOOK RATING
1..100
7861
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
65
Fair valued
PROFIT vs RISK RATING
1..100
10015
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
4037
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
275

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ANVS's Valuation (43) in the null industry is in the same range as MDGL (65) in the Pharmaceuticals Other industry. This means that ANVS’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (15) in the Pharmaceuticals Other industry is significantly better than the same rating for ANVS (100) in the null industry. This means that MDGL’s stock grew significantly faster than ANVS’s over the last 12 months.

MDGL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as ANVS (100) in the null industry. This means that MDGL’s stock grew similarly to ANVS’s over the last 12 months.

MDGL's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as ANVS (40) in the null industry. This means that MDGL’s stock grew similarly to ANVS’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as ANVS (100) in the null industry. This means that MDGL’s stock grew similarly to ANVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANVSMDGL
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 30 days ago
83%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 17 days ago
90%
Bearish Trend 10 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ANVS
Daily Signal:
Gain/Loss:
MDGL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EARN5.330.05
+0.95%
Ellington Credit Company
BKT11.060.04
+0.36%
BlackRock Income Trust
TDSB24.300.07
+0.27%
ETC Cabana Target Beta ETF
SPGM77.530.05
+0.06%
SPDR® Portfolio MSCI Global Stk Mkt ETF
BULU6.33-0.36
-5.32%
T-REX 2X Long BULL Daily Target ETF

ANVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANVS has been loosely correlated with ADXN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ANVS jumps, then ADXN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANVS
1D Price
Change %
ANVS100%
-1.64%
ADXN - ANVS
43%
Loosely correlated
-2.56%
ALGS - ANVS
41%
Loosely correlated
-3.90%
ERAS - ANVS
37%
Loosely correlated
+1.46%
MDGL - ANVS
36%
Loosely correlated
-0.65%
VYGR - ANVS
36%
Loosely correlated
+0.25%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ALXO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ALXO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
-0.65%
ALXO - MDGL
56%
Loosely correlated
-2.21%
IPHA - MDGL
44%
Loosely correlated
+2.94%
GHRS - MDGL
43%
Loosely correlated
-1.45%
LCTX - MDGL
43%
Loosely correlated
-1.79%
CVM - MDGL
43%
Loosely correlated
+0.64%
More